Evidence map›Paper›PMID 32501445›Full record

ArticleBiosafety and health2019

SINS model in the management of biosafety level 2 laboratories: exploration and practice.

Xiaoxia Qiu, Jingqing Weng, Zhenggang Jiang, Congcong Yan, Hua Gu

Abstract read
In one paragraph

Article in Biosafety and health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Xiaoxia QiuZhejiang Provincial Center for Medical Science Technology & Education, Hangzhou 310000, China.
Jingqing WengZhejiang Provincial Center for Medical Science Technology & Education, Hangzhou 310000, China.
Zhenggang JiangProvincial Center for Disease Control and Prevention, Hangzhou 310000, China.
Congcong YanDepartment of Preventive Medicine, School of Medicine, Ningbo University, Ningbo 315000, China.
Hua GuZhejiang Provincial Center for Medical Science Technology & Education, Hangzhou 310000, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A significant number of biosafety level 2 (BSL-2) laboratories have been established in many countries for studies of various types of pathogenic agents and other infectious biological materials. The harmonized management of biological risks in such diverse laboratories thus appears as a real challenge. Zhejiang Province in China has taken the initiative to establish a comprehensively integrated laboratory biosafety management system called SINS (Standardization, Informatization, Normalization and Systematization). The SINS model system has been introduced and adopted in 1,721 BSL-2 laboratories in Zhejiang Province, and thus lead to an increase in the number of biosafety committees from 20% to more than 95% from 2007 to 2018, and the number of biosafety laboratory managers who knows biosafety-related laws and regulations increase from 52.7% to 83.7% from 2009 to 2017. Such achievements indicate that the successful implementation of SINS model has increased the effective control of biological risks in BSL-2 laboratories of the Zhejiang Province. SINS model and its main effects on leading the improvement of laboratory biosafety management was presented in this review. The SINS model helps to strengthen laboratory biosafety and thus effectively reduces occurrence of biosafety-related incidences. This model can potentially be used by other regions or countries where harmonized biosafety management system is still under-developing.

Indexed as

BiosafetyBSL-2 laboratoryManagementPathogenic agentsSINS model

Identifiers

PMID32501445
PMCPMC7148668

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.